Search hospitals > Iowa > Des Moines
Medical Oncology and Hematology Associates-Laurel
Claim this profileDes Moines, Iowa 50314
Global Leader in Cancer
Global Leader in Recurrence
Conducts research for Lung Cancer
Conducts research for Adenocarcinoma
Conducts research for Breast Cancer
166 reported clinical trials
2 medical researchers
Summary
Medical Oncology and Hematology Associates-Laurel is a medical facility located in Des Moines, Iowa. This center is recognized for care of Cancer, Recurrence, Lung Cancer, Adenocarcinoma, Breast Cancer and other specialties. Medical Oncology and Hematology Associates-Laurel is involved with conducting 166 clinical trials across 278 conditions. There are 2 research doctors associated with this hospital, such as Richard L. Deming and Mehmet S. Copur.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
HER2 positive
2Recurrence
Global LeaderStage IV
Stage III
Stage II
Top PIs
Richard L. DemingMercy Medical Center - Des Moines4 years of reported clinical research
Expert in Cancer
Expert in Breast Cancer
172 reported clinical trials
239 drugs studied
Mehmet S. CopurBethesda North Hospital12 years of reported clinical research
Studies Breast Cancer
Studies Ovarian Cancer
2 reported clinical trials
8 drugs studied
Clinical Trials running at Medical Oncology and Hematology Associates-Laurel
Breast Cancer
Melanoma
Multiple Myeloma
Cancer
Cutaneous Melanoma
Lung Cancer
Small Intestinal Adenocarcinoma
Small Cell Lung Cancer
Non-Small Cell Lung Cancer
Laryngeal Cancer
Chemotherapy Reduction After Surgery
for Breast Cancer
This trial studies how well paclitaxel, trastuzumab, and pertuzumab work in eliminating further chemotherapy after surgery in patients with HER2-positive stage II-IIIa breast cancer who have no cancer remaining at surgery (either in the breast or underarm lymph nodes) after pre-operative chemotherapy and HER2-targeted therapy. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Trastuzumab and pertuzumab are both a form of "targeted therapy" because they work by attaching themselves to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When these drugs attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Giving paclitaxel, trastuzumab, and pertuzumab may enable fewer chemotherapy drugs to be given without compromising patient outcomes compared to the usual treatment.
Recruiting1 award Phase 227 criteria
T-DM1 + Tucatinib
for Breast Cancer
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.
Recruiting1 award Phase 313 criteria
Questionnaire Choice
for Cancer Data Quality
The purpose of this study is to evaluate feasibility and acceptability of completing PROs among AYAs randomized to Choice PRO vs Fixed PRO.
Recruiting1 award N/A11 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Medical Oncology and Hematology Associates-Laurel?
Medical Oncology and Hematology Associates-Laurel is a medical facility located in Des Moines, Iowa. This center is recognized for care of Cancer, Recurrence, Lung Cancer, Adenocarcinoma, Breast Cancer and other specialties. Medical Oncology and Hematology Associates-Laurel is involved with conducting 166 clinical trials across 278 conditions. There are 2 research doctors associated with this hospital, such as Richard L. Deming and Mehmet S. Copur.